Our top pick for
Oragenics, Inc is a biotechnology business based in the US. Oragenics shares (OGEN) are listed on the NYSE MKT and all prices are listed in US Dollars. Oragenics employs 7 staff and has a market cap (total outstanding shares value) of USD$123.5 million.
|52-week range||USD$0.36 - USD$2.09|
|50-day moving average||USD$1.03|
|200-day moving average||USD$0.698|
|Wall St. target price||USD$3|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.511|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-92.15%|
|Return on equity TTM||-168.22%|
|Market capitalisation||USD$123.5 million|
TTM: trailing 12 months
There are currently 3.4 million Oragenics shares held short by investors – that's known as Oragenics's "short interest". This figure is 60.6% up from 2.1 million last month.
There are a few different ways that this level of interest in shorting Oragenics shares can be evaluated.
Oragenics's "short interest ratio" (SIR) is the quantity of Oragenics shares currently shorted divided by the average quantity of Oragenics shares traded daily (recently around 41.9 million). Oragenics's SIR currently stands at 0.08. In other words for every 100,000 Oragenics shares traded daily on the market, roughly 80 shares are currently held short.
However Oragenics's short interest can also be evaluated against the total number of Oragenics shares, or, against the total number of tradable Oragenics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oragenics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Oragenics shares in existence, roughly 40 shares are currently held short) or 0.0417% of the tradable shares (for every 100,000 tradable Oragenics shares, roughly 42 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Oragenics.
Find out more about how you can short Oragenics stock.
We're not expecting Oragenics to pay a dividend over the next 12 months.
Oragenics's shares were split on a 1:10 basis on 22 January 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oragenics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Oragenics shares which in turn could have impacted Oragenics's share price.
Over the last 12 months, Oragenics's shares have ranged in value from as little as $0.36 up to $2.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Oragenics's is 0.262. This would suggest that Oragenics's shares are less volatile than average (for this exchange).
Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring compound for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against dental caries, or tooth decay. Oragenics, Inc. has collaboration agreements with Precigen, Inc. and its subsidiary, Intrexon Actobiotics NV to develop AG013; and a license agreement with LPThera LLC to develop LPT3-04. It also has a process development and drug substance manufacturing agreement with Avid Bioservices, Inc. for coronavirus vaccine. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.